Basic information |
Metabolite name | N-Acetyl aspartate/(Creatine and Phosphocreatine) ratio |
N/A | |
N/A | |
N/A | |
Synonyms | N-acetylasparte/(Creatine and Phosphocreatine) ratio; |
No. of studies | 54 |
Relationship between N-Acetyl aspartate/(Creatine and Phosphocreatine) ratio and depression (count: 54) |
Study | Study Type | Comparison groups | Tissue | Organism | Up/Down regulated |
Study M1050 | Type1 | MDD without gastrointestinal symptoms group vs. control group | Anterior cingulate gyrus | Human | Down |
Study M1050 | Type1 | MDD with gastrointestinal symptoms group vs. control group | Anterior cingulate gyrus | Human | Down |
Study M1050 | Type1 | MDD without gastrointestinal symptoms group vs. control group | Thalamus | Human | Down |
Study M1050 | Type1 | MDD with gastrointestinal symptoms group vs. control group | Thalamus | Human | Down |
Study M211 | Type2 | depression group post-treatment vs. baseline | Brain | Human | Up |
Study M227 | Type1 | depression group vs. control group | Dorsolateral prefrontal cortex | Human | Down |
Study M228 | Type1 | depression group vs. control group | Frontal lobe | Human | Down |
Study M238 | Type1 | depression group vs. control group | Caudate | Human | Down |
Study M249 | Type1 | TBI with depression group vs. control group | Basal ganglia | Human | Down |
Study M251 | Type2 | depression group post-treatment vs. pre-treatment | Medial frontal cortex | Human | Up |
Study M257 | Type1 | depression group vs. control group | Thalamus | Human | Down |
Study M259 | Type1 | depression group vs. control group | Hippocampus | Human | Down |
Study M259 | Type1 | depression group vs. control group | Frontal lobe | Human | Down |
Study M259 | Type2 | SSRI-treated depression group post-treatment vs. pre-treatment | Frontal lobe | Human | Up |
Study M259 | Type2 | SSRI-treated depression group post-treatment vs. pre-treatment | Hippocampus | Human | Up |
Study M261 | Type1 | depression group vs. control group | Hippocampus | Human | Down |
Study M265 | Type1 | unmedicated depression group vs. control group | Frontal white matter | Human | Down |
Study M268 | Type1 | depression group vs. control group | Hippocampus | Human | Down |
Study M273 | Type2 | fluoxetine group post-treatment vs. pre-treatment | Hippocampus | Human | Up |
Study M273 | Type2 | fluoxetine group post-treatment vs. pre-treatment | Frontal lobe | Human | Up |
Study M273 | Type2 | EA + fluoxetine group post-treatment vs. pre-treatment | Frontal lobe | Human | Up |
Study M273 | Type2 | EA + fluoxetine group post-treatment vs. pre-treatment | Hippocampus | Human | Up |
Study M275 | Type1 | depression group vs. control group | Thalamus | Human | Down |
Study M275 | Type1 | depression group vs. control group | Hippocampus | Human | Down |
Study M275 | Type2 | paroxetine-treated depression group post-treatment vs. pre-treatment | Hippocampus | Human | Up |
Study M275 | Type2 | paroxetine-treated depression group post-treatment vs. pre-treatment | Thalamus | Human | Up |
Study M284 | Type2 | MS + EE group vs. MS group | Hippocampus | Sprague-Dawley rat | Up |
Study M288 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
Study M288 | Type2 | CUMS + escitalopram group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
Study M298 | Type2 | escitalopram group vs. placebo group | Medial frontal cortex | Human | Up |
Study M300 | Type2 | depression group post-treatment vs. pre-treatment | Hippocampus | Human | Up |
Study M301 | Type1 | depression group vs. control group | Dorsolateral prefrontal white matter | Human | Down |
Study M306 | Type1 | depression group vs. control group | Hippocampus | Human | Down |
Study M308 | Type1 | moderate depression group vs. control group | Prefrontal cortex | Human | Down |
Study M311 | Type1 | OSAHS group vs. control group | Frontal white matter | Human | Down |
Study M315 | Type1 | AD with depression group vs. AD without depression group | Anterior cingulate gyrus | Human | Down |
Study M319 | Type1 | depression group vs. control group | Prefrontal cortex | Human | Down |
Study M319 | Type1 | depression group vs. control group | Hippocampus | Human | Down |
Study M320 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
Study M320 | Type2 | rTMS responder group post-treatment vs. pre-treatment | Anterior cingulate cortex | Human | Up |
Study M320 | Type4 | rTMS responder group vs. rTMS non-responder group | Anterior cingulate cortex | Human | Up |
Study M321 | Type1 | depression group vs. control group | Prefrontal lobe white matter | Human | Down |
Study M326 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
Study M326 | Type2 | MBCT-treated depression group post-treatment vs. pre-treatment | Anterior cingulate cortex | Human | Up |
Study M332 | Type1 | depression group vs. control group | Dorsolateral prefrontal white matter | Human | Down |
Study M334 | Type1 | depression group vs. control group | Dorsal prefrontal cortex | Human | Down |
Study M343 | Type1 | severe depression group vs. control group | Thalamus | Human | Down |
Study M343 | Type1 | moderate depression group vs. control group | Thalamus | Human | Down |
Study M343 | Type1 | depression group vs. control group | Thalamus | Human | Down |
Study M351 | Type1 | depression group vs. control group | Thalamus | Human | Down |
Study M363 | Type2 | ECT-treated depression group post-treatment vs. pre-treatment | Hippocampus | Human | Down |
Study M365 | Type1 | depression group vs. control group | Prefrontal cortex | Human | Down |
Study M366 | Type1 | CMS group vs. control group | Ventral hippocampus | Long-Evans rat | Up |
Study M367 | Type1 | METH group vs. control group | Frontal cortex | C57BL/6 mouse | Down |
Study M468 | Type1 | depression group vs. control group | Prefrontal cortex | Human | Up |
Study M468 | Type1 | depression group vs. control group | Hippocampus | Human | Up |
Study M468 | Type2 | depression group post-exercise vs. pre-exercise | Hippocampus | Human | Down |
Study M538 | Type2 | MDD group, after rTMS treatment vs. baseline | Dorsolateral prefrontal cortex | Human | Up |
Study M580 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
Study M580 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
Study M612 | Type1 | MDD group vs. control group | Anterior cingulate cortex | Human | Down |
Study M624 | Type1 | cognitive impairment with depression group vs. cognitive impairment group | Frontal white matter | Human | Down |
Study M624 | Type1 | cognitive impairment with depression group vs. cognitive impairment group | Hippocampus | Human | Up |
Study M637 | Type1 | MDD group vs. control group | Prefrontal cortex | Human | Down |
Study M660 | Type1 | ESRD with depression vs. ESRD without depression | Frontal lobe | Human | Down |
Study M694 | Type1 | depression group vs. control group | Posterior cingulate | Human | Down |
Study M752 | Type1 | PSD group vs. control group | Hippocampus | Wistar rat | Down |
Study M752 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
Study M752 | Type1 | PSD group vs. control group | Prefrontal cortex | Wistar rat | Down |
Study M752 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Down |
Study M752 | Type2 | PSD + Yi-nao-jie-yu decoction group vs. PSD group | Hippocampus | Wistar rat | Up |
Study M752 | Type2 | PSD + Yi-nao-jie-yu decoction group vs. PSD group | Prefrontal cortex | Wistar rat | Up |
Study M765 | Type1 | MDD group vs. control group | Lenticular nucleus | Human | Down |
Study M812 | Type1 | MDD group vs. control group | Hippocampus | Human | Down |
Study M855 | Type1 | MDD group vs. control group | Thalamus | Human | Up |
Study M855 | Type1 | MDD group vs. control group | Prefrontal cortex | Human | Down |
Study M864 | Type2 | psilocybin group, posttreatment vs. baseline | Anterior cingulate cortex | Human | Down |
Study M895 | Type1 | MDD with childhood trauma group vs. control group | Anterior cingulate cortex | Human | Down |
Study M895 | Type1 | MDD with childhood trauma group vs. control group | Putamen | Human | Down |
Study M895 | Type1 | MDD without childhood trauma group vs. control group | Cerebellum | Human | Up |
Study M895 | Type1 | MDD without childhood trauma group vs. control group | Anterior cingulate cortex | Human | Down |
Study M895 | Type1 | MDD with childhood trauma group vs. control group | Cerebellum | Human | Up |
Study M895 | Type1 | MDD without childhood trauma group vs. control group | Putamen | Human | Down |
Study M899 | Type1 | depression with non-suicidal self-injury group vs. control group | Thalamus | Human | Up |
Study M899 | Type1 | depression without non-suicidal self-injury group vs. control group | Prefrontal cortex | Human | Down |
Study M899 | Type1 | depression with non-suicidal self-injury group vs. control group | Lenticular nucleus | Human | Down |
Study M914 | Type1 | depression with anxiety group vs. control group | Dorsal anterior cingulate cortex | Human | Down |
Study M914 | Type1 | depression with anxiety group vs. control group | Pregenual anterior cingulate cortex | Human | Down |
Study M925 | Type1 | MDD group vs. control group | Prefrontal cortex | Human | Down |
Study M954 | Type2 | modified electroconvulsive therapy group vs. control treatment group | Prefrontal white matter and anterior cingulate cortex | Human | Up |
Study M973 | Type1 | MDD group vs. control group | Cerebellum | Human | Down |